157 related articles for article (PubMed ID: 16230873)
1. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy.
Juszczyk MA; Seip RL; Thompson PD
Prev Cardiol; 2005; 8(4):197-9. PubMed ID: 16230873
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
3. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
Insull W; Ghali JK; Hassman DR; Y As JW; Gandhi SK; Miller E;
Mayo Clin Proc; 2007 May; 82(5):543-50. PubMed ID: 17493418
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
Hirsch M; O'donnell J; Olsson A
Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
[TBL] [Abstract][Full Text] [Related]
6. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
Ballantyne CM; Raichlen JS; Cain VA
J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
[TBL] [Abstract][Full Text] [Related]
7. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
8. Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
Kurabayashi M; Yamazaki T;
J Atheroscler Thromb; 2008 Dec; 15(6):314-23. PubMed ID: 19060425
[TBL] [Abstract][Full Text] [Related]
9. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Montouchet C; Ruff L; Balu S
J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.
Park JS; Kim YJ; Choi JY; Kim YN; Hong TJ; Kim DS; Kim KY; Jeong MH; Chae JK; Oh SK; Seong IW
Korean J Intern Med; 2010 Mar; 25(1):27-35. PubMed ID: 20195400
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
Asztalos BF; Le Maulf F; Dallal GE; Stein E; Jones PH; Horvath KV; McTaggart F; Schaefer EJ
Am J Cardiol; 2007 Mar; 99(5):681-5. PubMed ID: 17317371
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.
Rawlings R; Nohria A; Liu PY; Donnelly J; Creager MA; Ganz P; Selwyn A; Liao JK
Am J Cardiol; 2009 Feb; 103(4):437-41. PubMed ID: 19195498
[TBL] [Abstract][Full Text] [Related]
13. Statin wars: emphasis on potency vs event reduction and safety?
Lavie CJ; Milani RV; O'Keefe JH
Mayo Clin Proc; 2007 May; 82(5):539-42. PubMed ID: 17493417
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
Leiter LA; Rosenson RS; Stein E; Reckless JP; Schulte KL; Schleman M; Miller P; Palmer M; Sosef F;
Atherosclerosis; 2007 Oct; 194(2):e154-64. PubMed ID: 17229426
[TBL] [Abstract][Full Text] [Related]
15. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels.
Ai M; Otokozawa S; Asztalos BF; Nakajima K; Stein E; Jones PH; Schaefer EJ
Am J Cardiol; 2008 Feb; 101(3):315-8. PubMed ID: 18237592
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Hirsch M; O'Donnell JC; Jones P
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
Faergeman O; Hill L; Windler E; Wiklund O; Asmar R; Duffield E; Sosef F;
Cardiology; 2008; 111(4):219-28. PubMed ID: 18434729
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting.
Bullano MF; Kamat S; Wertz DA; Borok GM; Gandhi SK; McDonough KL; Willey VJ
Am J Health Syst Pharm; 2007 Feb; 64(3):276-84. PubMed ID: 17244877
[TBL] [Abstract][Full Text] [Related]
19. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
